Revisiting beta thalassemia intermedia: past, present, and future prospects

References

• Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373–383.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Rivella S, Vichinsky E, et al. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833–844.
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135–1146.
   PubMed Web of Science ®Google Scholar
• Haddad A, Tyan P, Radwan A, et al. beta-thalassemia intermedia: a bird’s-eye view. Turk J Haematol. 2014;31(1):5–16.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl. 1):S3–S6.
   PubMed Web of Science ®Google Scholar
• Galanello R, Cao A. Relationship between genotype and phenotype – thalassemia intermedia. Cooleys Anemia. 1998;850:325–333.
   Web of Science ®Google Scholar
• Danjou F, Anni F, Galanello R. Beta-thalassemia: from genotype to phenotype. Haematol-Hematol J. 2011;96(11):1573–1575.
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation; 2013.
   Google Scholar
• Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2(4):245–255.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Mazza U, Roetto A, et al. Genetic interactions in thalassemia-intermedia – analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-Lcr hypersensitive site-2 and site-4 in Italian patients. Am J Hematol. 1995;48(2):82–87.
   PubMed Web of Science ®Google Scholar
• Weatherall D. 2003 William Allan Award address – the thalassemias: the role of molecular genetics in an evolving global health problem. Am J Hum Genet. 2004;74(3):385–392.
   PubMed Web of Science ®Google Scholar
• Thein SL. Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol. 2004;124(3):264–274.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: a clinical perspective. Csh Perspect Med. 2012;2(7): a013482.
   Google Scholar
• Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl. 1):S12–S15.
   PubMed Web of Science ®Google Scholar
• Ross P, Logan W. Roentgen findings in extramedullary hematopoiesis. Am J Roentgenol Radium Ther Nucl Med. 1969;106(3):604–613.
   PubMedGoogle Scholar
• Aessopos A, Tassiopoulos S, Farmakis D, et al. Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia. Ann Thorac Surg. 2006;81(6):2037–2043.
   PubMed Web of Science ®Google Scholar
• Chuang CK, Chu SH, Fang JT, et al. Adrenal extramedullary hematopoietic tumor in a patient with beta-thalassemia. J Formos Med Assoc. 1998;97(6):431–433.
   PubMed Web of Science ®Google Scholar
• Kumar A, Aggarwal S, de Tilly LN. Case of the season. Thalassemia major with extramedullary hematopoiesis in the liver. Semin Roentgenol. 1995;30(2):99–101.
   PubMedGoogle Scholar
• Thuret I. Current management of thalassemia intermedia. Transfus Clin Biol. 2014;21(4-5):143–149.
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488–491.
   PubMed Web of Science ®Google Scholar
• Taher AT, Otrock ZK, Uthman I, et al. Thalassemia and hypercoagulability. Blood Rev. 2008;22(5):283–292.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8(10):2152–2158.
   PubMed Web of Science ®Google Scholar
• Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of beta-thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014;129(3):338–345.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254–2265.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Lancaster JR, Jr., Freeman BA, et al. Nitric oxide’s reactions with hemoglobin: a view through the SNO-storm. Nat Med. 2003;9(5):496–500.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with beta thalassemia intermedia. Eur J Intern Med. 2011;22(6):607–610.
   PubMed Web of Science ®Google Scholar
• Manfre L, Giarratano E, Maggio A, et al. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol. 1999;173(6):1477–1480.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Karimi M, et al. Cerebral infarction in beta-thalassemia intermedia: breaking the silence. Thromb Res. 2012;130(5):695–702.
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with beta-thalassemia intermedia. Ann Hematol. 2012;91(12):1833–1838.
   PubMed Web of Science ®Google Scholar
• Moukhadder HM, Halawi R, Cappellini MD, et al. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer. 2017;123(5):751–758.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114–117.
   PubMed Web of Science ®Google Scholar
• Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150(2):245–247.
   PubMed Web of Science ®Google Scholar
• Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin. 2010;34(3):221–226.
   PubMed Web of Science ®Google Scholar
• Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl. 1):S79–S86.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–430.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Muraca GM, O’Donnell A, et al. Studies in haemoglobin E beta-thalassaemia. Br J Haematol. 2008;141(3):388–397.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Daar S, et al. Serum ferritin levels and morbidity in beta-thalassemia intermedia: a 10-year Cohort study. Blood. 2012;120(21):1021.
   Web of Science ®Google Scholar
• Musallam KM, Taher AT, Duca L, et al. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with beta thalassemia intermedia. Blood Cells Mol Dis. 2011;47(4):232–234.
   PubMed Web of Science ®Google Scholar
• Matta BN, Abbas O, Maakaron JE, et al. Leg ulcers in patients with beta-thalassaemia intermedia: a single centre’s experience. J Eur Acad Dermatol Venereol. 2014;28(9):1245–1250.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291–304.
   PubMed Web of Science ®Google Scholar
• Sanctis VD, Tangerini A, Testa MR, et al. Final height and endocrine function in thalassaemia intermedia. J Pediatr Endocrinol Metab. 1998;11(Suppl. 3):965–971.
   PubMed Web of Science ®Google Scholar
• Inati A, Noureldine MA, Mansour A, et al. Endocrine and bone complications in beta-thalassemia intermedia: current understanding and treatment. Biomed Res Int. 2015;2015:813098.
   PubMed Web of Science ®Google Scholar
• Karamifar H, Shahriari M, Sadjadian N. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran. East Mediterr Health J. 2003;9(1–2):55–60.
   PubMedGoogle Scholar
• Monge L, Pinach S, Caramellino L, et al. The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. Diabetes Metab. 2001;27(2 Pt 1):149–154.
   PubMed Web of Science ®Google Scholar
• Argyropoulou MI, Kiortsis DN, Astrakas L, et al. Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study. Eur Radiol. 2007;17(12):3025–3030.
   PubMed Web of Science ®Google Scholar
• Chern JP, Lin KH, Lu MY, et al. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diabetes Care. 2001;24(5):850–854.
   PubMed Web of Science ®Google Scholar
• Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with beta thalassemia major. Bone. 2011;48(3):425–432.
   PubMed Web of Science ®Google Scholar
• Skordis N, Christou S, Koliou M, et al. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab. 1998;11(Suppl. 3):935–943.
   PubMed Web of Science ®Google Scholar
• Nassar AH, Usta IM, Rechdan JB, et al. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol. 2006;81(7):499–502.
   PubMed Web of Science ®Google Scholar
• Nassar AH, Usta IM, Taher AM. Beta-thalassemia intermedia and pregnancy: should we anticoagulate? J Thromb Haemost. 2006;4(6):1413–1414.
   PubMed Web of Science ®Google Scholar
• Nassar AH, Naja M, Cesaretti C, et al. Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica. 2008;93(10):1586–1587.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD, et al. Optimal management of beta thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523.
   PubMed Web of Science ®Google Scholar
• Tuck SM, Jensen CE, Wonke B, et al. Pregnancy management and outcomes in women with thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(Suppl. 3):923–928.
   PubMed Web of Science ®Google Scholar
• Mojtahedzadeh F, Kosaryan M, Mahdavi MR, et al. The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial. Arch Iran Med. 2006;9(3):266–268.
   PubMedGoogle Scholar
• Puliyel M, Sposto R, Berdoukas VA, et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol. 2014;89(4):391–394.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Daar S, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with beta-thalassemia intermedia: the ORIENT study. Haematologica. 2014;99(11):e218–e221.
   PubMed Web of Science ®Google Scholar
• Taher A, El Rassi F, Isma’eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584–1586.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49(3):329–332.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327–331.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5 mg/g liver iron concentration threshold and its association with morbidity in patients with beta-thalassemia intermedia. Blood Cells Mol Dis. 2013;51(1):35–38.
   PubMed Web of Science ®Google Scholar
• Taher A, Musallam KM, El Rassi F, et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5):569–572.
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Curr Med Res Opin. 2016;32(1):191–204.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–3462.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). TIF publication. 2014 (20).
   Google Scholar
• Musallam KM, Angastiniotis M, Eleftheriou A, et al. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol-Basel. 2013;130(2):64–73.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485–1493.
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD, Aydinok Y, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016;57:23–29.
   PubMed Web of Science ®Google Scholar
• Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92(5):420–428.
   PubMed Web of Science ®Google Scholar
• Saliba AN, Taher AT. Morbidities in non-transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):82–94.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Cappellini MD, et al. Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood. 2013;121(12):2199–2212. quiz 372.
   PubMed Web of Science ®Google Scholar
• Preza GC, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011;121(12):4880–4888.
   PubMed Web of Science ®Google Scholar
• Casu C, Goldberg A, Nemeth E, et al. Treatment with minihepcidin peptide improves anemia and iron overload in a mouse model of thalassemia intermedia. Blood. 2013;122(21):431.
   Web of Science ®Google Scholar
• Casu C, Oikonomidau R, Shah Y, et al. Concurrent treatment with minhepcidin and deferiprone improves anemia and enhances reduction of spleen iron in a mouse model of non-transfusion dependent thalassemia. Blood. 2014;124(21):748.
   Web of Science ®Google Scholar
• Gardenghi S, Ramos P, Roy CN, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemia. Blood. 2010;116(21):443–444.
   Web of Science ®Google Scholar
• Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012;120(18):3829–3836.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221–230.
   PubMed Web of Science ®Google Scholar
• Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012;119(21):5021–5029.
   PubMed Web of Science ®Google Scholar
• Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013;123(4):1531–1541.
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Toudjarska I, Sendamarai AK, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood. 2013;121(7):1200–1208.
   PubMed Web of Science ®Google Scholar
• Casu C, Aghajan M, Oikonomidou PR, et al. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica. 2016;101(1):e8–e11.
   PubMed Web of Science ®Google Scholar
• Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood. 2008;112(3):875–885.
   PubMed Web of Science ®Google Scholar
• Taher A, Hussain I, Cappellini MD. Thalassemia intermedia: revisited. Blood Cell Mol Dis. 2006;37(1):12–20.
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Karakas Z, Cassinerio E, et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from single-arm, multicenter, phase 2a truth study. Blood. 2016;128(22):852.
   PubMed Web of Science ®Google Scholar
• Melchiori L, Gardenghi S, Guy EC, et al. Use of Jak2 inhibitors to limit ineffective erythropoiesis and iron absorption in mice affected by beta-thalassemia and other disorders of red cell production. Blood. 2009;114(22):798.
   Web of Science ®Google Scholar
• Li HH, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16(2):177–182.
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744–752.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, Origa R, et al. A phase 2a, open-label, dose-finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (beta)-thalassemia: interim results. Blood. 2013;122(21):3448.
   Web of Science ®Google Scholar
• Taher AT, Cappellini MD. Management of non-transfusion-dependent thalassemia: a practical guide. Drugs. 2014;74(15):1719–1729.
   PubMed Web of Science ®Google Scholar
• Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-20. Bone Marrow Transpl. 2016;51(4):536–541.
   PubMed Web of Science ®Google Scholar
• King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089–3094.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122(6):1072–1078.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation-therapy. New Engl J Med. 1993;329(12):840–844.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811–820.
   PubMed Web of Science ®Google Scholar
• Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann NY Acad Sci. 2005;1054:308–316.
   PubMed Web of Science ®Google Scholar
• Raja JV, Rachchh MA, Gokani RH. Recent advances in gene therapy for thalassemia. J Pharm Bioallied Sci. 2012;4(3):194–201.
   PubMedGoogle Scholar
• Rai P, Malik P. Gene therapy for hemoglobin disorders – a mini-review. J Rare Dis Res Treat. 2016;1(2):25–31.
   PubMedGoogle Scholar
• Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121–131.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter JB, Musallam KM, et al. Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. Eur J Intern Med. 2016;28:91–96.
   PubMed Web of Science ®Google Scholar